[1]

Siegel RL, Miller KD, Wagle NS, Jemal A. 2023. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians 73:17−48

doi: 10.3322/caac.21763
[2]

Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. 2023. Colorectal cancer statistics, 2023. CA: a cancer journal for clinicians 73:233−54

doi: 10.3322/caac.21772
[3]

Xi Y, Xu P. 2021. Global colorectal cancer burden in 2020 and projections to 2040. Translational Oncology 14:101174

doi: 10.1016/j.tranon.2021.101174
[4]

Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. 2019. Colorectal cancer. Lancet 394:1467−80

doi: 10.1016/S0140-6736(19)32319-0
[5]

Kim CH, Huh JW, Kim HR, Kim YJ. 2014. Prognostic comparison between number and distribution of lymph node metastases in patients with right-sided colon cancer. Annals of Surgical Oncology 21:1361−68

doi: 10.1245/s10434-013-3426-3
[6]

Lebowitz JJ, Banerjee A, Qiao C, Bunzow JR, Williams JT, et al. 2023. Synaptotagmin-1 is a Ca2+ sensor for somatodendritic dopamine release. Cell Reports 42:111915

doi: 10.1016/j.celrep.2022.111915
[7]

Haberman Y, Ziv I, Gorzalczany Y, Hirschberg K, Mittleman L, et al. 2007. Synaptotagmin (Syt) IX is an essential determinant for protein sorting to secretory granules in mast cells. Blood 109:3385−92

doi: 10.1182/blood-2006-07-033126
[8]

Wolfes AC, Dean C. 2020. The diversity of synaptotagmin isoforms. Current Opinion in Neurobiology 63:198−209

doi: 10.1016/j.conb.2020.04.006
[9]

Chapman ER. 2008. How does synaptotagmin trigger neurotransmitter release? Annual Review of Biochemistry 77:615−41

doi: 10.1146/annurev.biochem.77.062005.101135
[10]

Tokuoka H, Goda Y. 2003. Synaptotagmin in Ca2+ -dependent exocytosis: dynamic action in a flash. Neuron 38:521−24

doi: 10.1016/S0896-6273(03)00290-3
[11]

Kanda M, Shimizu D, Tanaka H, Tanaka C, Kobayashi D, et al. 2018. Significance of SYT8 for the detection, prediction, and treatment of peritoneal metastasis from gastric cancer. Annals of Surgery 267:495−503

doi: 10.1097/SLA.0000000000002096
[12]

Kanda M, Nomoto S, Oya H, Takami H, Shimizu D, et al. 2016. The expression of melanoma-associated antigen D2 both in surgically resected and serum samples serves as clinically relevant biomarker of gastric cancer progression. Annals of Surgical Oncology 23(Suppl 2):S214−S221

doi: 10.1245/s10434-015-4457-8
[13]

Wang K, Xiao H, Zhang J, Zhu D. 2018. Synaptotagmin7 is overexpressed in colorectal cancer and regulates colorectal cancer cell proliferation. Journal of Cancer 9:2349−56

doi: 10.7150/jca.25098
[14]

Fu Z, Liang X, Shi L, Tang L, Chen D, et al. 2021. SYT8 promotes pancreatic cancer progression via the TNNI2/ERRα/SIRT1 signaling pathway. Cell Death Discovery 7:390

doi: 10.1038/s41420-021-00779-4
[15]

Fei Z, Gao W, Xie R, Feng G, Chen X, et al. 2019. Synaptotagmin-7, a binding protein of P53, inhibits the senescence and promotes the tumorigenicity of lung cancer cells. Bioscience Reports 39:BSR20181298

doi: 10.1042/BSR20181298
[16]

Pedersen NM, Wenzel EM, Wang L, Antoine S, Chavrier P, et al. 2020. Protrudin-mediated ER-endosome contact sites promote MT1-MMP exocytosis and cell invasion. The Journal of Cell Biology 219:e202003063

doi: 10.1083/jcb.202003063
[17]

Bajaj R, Rodriguez BL, Russell WK, Warner AN, Diao L, et al. 2022. Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis. Cell Reports 40:111429

doi: 10.1016/j.celrep.2022.111429
[18]

Mayorga LS, Tomes CN, Belmonte SA. 2007. Acrosomal exocytosis, a special type of regulated secretion. IUBMB Life 59:286−92

doi: 10.1080/15216540701222872
[19]

Kanda M, Shimizu D, Tanaka H, Tanaka C, Kobayashi D, et al. 2018. Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer. The British Journal of Surgery 105:1349−58

doi: 10.1002/bjs.10876
[20]

Suo H, Xiao N, Wang K. 2022. Potential roles of synaptotagmin family members in cancers: recent advances and prospects. Frontiers in medicine 9:968081

doi: 10.3389/fmed.2022.968081